[A19-34] Enzalutamide (prostate cancer) - Addendum to Commission A18-80
Last updated 16.05.2019
Project no.:
A19-34
Commission:
Commission awarded on 08.04.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
High-risk non-metastatic castration-resistant prostate cancer
Result of dossier assessment:
Conclusion of dossier assessment A18-80 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-80 | Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-05-16 A G-BA decision was published.